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  Dose of PRT062607 
PK 
Parameter Units 11 mg N 33 mg N 66 mg N 110 mg N 
Cmax (ng/mL) 16.1 (9.81) 6 61.4 (36.6) 6 119 (80.8) 6 223 (109) 6 
          
Tmaxa (hr) 1.00  
(0.500, 1.00) 6 
2.00 
(0.533, 4.00) 6 
2.53 
(2.00, 4.00) 6 
3.03 
(2.00, 6.00) 6 
          
AUC0-24 (ng*hr/mL 106 (46.7) 6 624 (369) 6 1327 (824) 6 2341 (1143) 6 
 a Median (Min, Max) presented for Tmax. 




Mean Plasma Concentration-Time Profiles for PRT062607 on Day 1 (MAD)
Mean (SD) Plasma PK Parameters for PRT062607 on Day 1 (MAD)
PRT62607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures 
Following Oral Dosing in Healthy Volunteers
Coffey et al
Supplemental Figure S2:  PK parameters following the first oral administration of PRT062607 in the 
MAD study. Plasma concentrations (y-axis, in ng/ml) over time (x-axis, in hours) following the first oral dose 
from the MAD study (A).  Dose groups are represented by symbols, as shown.  The summary table (B) depicts 
mean (SD) PK parameters for each dose level on day 1.  
